APPROACHES TO INCREASE EQUITABLE ACCESS TO AND DELIVERY OF QUALITY OF CARE WITH BISPECIFIC ANTIBODIES FOR PATIENTS WITH MULTIPLE MYELOMA

PFIZER, S.A

Object

Topic: Multiple Myeloma. 

Destination: Pfizer launches a call for funding for projects that promote the quality of care and best practices around the treatment of patients with relapsed/refractory Multiple Myeloma receiving treatment with a biospecific antibody.

Budget: 250,000€/project.

Duration: Maximum 2 years.

Are you interested in this call?

Are you interested?

Fill out the form below to receive more information: